Cara Therapeutics reported $-31307000 in Operating Profit for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Acadia Pharmaceuticals ACAD:US USD -46063000 15.2M
Acelrx Pharmaceuticals ACRX:US USD -6632000 6.94M
Cara Therapeutics CARA:US USD -31307000 7.46M
Chugai Pharma 4519:JP JPY 149.47B 52.59B
Endo International Ordinary Shares ENDP:US USD -636822000 1.1B
Halozyme Therapeutics HALO:US USD 74.51M 6.07M
Horizon Pharma HZNP:US USD 173.93M 13.33M
JAZZ PHA JAZZ:US USD -263386000 288.15M
Johnson & Johnson JNJ:US USD 4.2B 1.62B
Neurocrine Biosciences NBIX:US USD 103.4M 15.6M
Pacira Pharmaceuticals PCRX:US USD -9893000 31.18M
Pfizer PFE:US USD 5.17B 4.24B
Revance Therapeutics RVNC:US USD -144411000 66.93M
Supernus Pharmaceuticals SUPN:US USD 34.33M 35.86M
Teva Pharmaceutical Industries TEVA:US USD -855000000 1.27B
Vanda Pharmaceuticals VNDA:US USD 6.63M 2.72M